Resources & Programs
RSV Connection
RSV Connection™ is designed to assist your practice by making the Synagis® (palivizumab) referral process more efficient. Here are some of the key features of the program:
- RSV Connection enables you to submit all Synagis referrals to one fax number (1-866-252-1749), year-round. You can submit referrals all year as you identify candidates for Synagis, rather than waiting until the beginning of the season. In addition, referrals can be submitted on the RSV Connection Synagis Universal Referral form, or on any form required by the distributor or health plan.
- RSV Connection reviews all referral forms for completeness and routes them to the designated distributor or health plan. Approximately 40% of referrals arrive at RSV Connection with important information missing. Incomplete referrals can create potential delays in the processing of the referral at the distributor. After RSV Connection has worked with your office to acquire the missing information, 92% of the referrals that went to the distributor were considered complete.
- RSV Connection also provides a single point of contact for reimbursement assistance through the Synagis Reimbursement Hotline. For example, if you are unsure of which distributor can provide treatment for your patient, RSV Connection and the Synagis reimbursement hotline can, upon your request, research which distributors are associated with the health plan and provide you options to select a distributor. Other Hotline services include patient co-pay assistance, help with coverage denial appeals, PA assistance, and benefit verification.
- Finally, RSV Connection offers the option to complete and submit referrals electronically,
request Hotline reimbursement services, and check status of referrals via the RSV Connection provider
portal at www.rsvconnection.com/referrals. In
addition, on the provider portal you can download referral forms for specific distributors and health
plans in your state.
Ask your MedImmune representative for more information about RSV Connection.
Important Safety Information
Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), infants with a history of premature birth (≤35 weeks gestational age), and children with hemodynamically significant congenital heart disease (CHD). Synagis has been used in more than one million children in the U.S. since its introduction in 1998. The first dose of Synagis should be administered prior to commencement of the RSV season. Patients, including those who develop an RSV infection, should continue to receive monthly doses throughout the season.
Synagis should not be used in pediatric patients with a history of severe prior reaction to Synagis or its components. Cases of anaphylaxis were reported following re-exposure to Synagis and severe acute hypersensitivity reactions have also been reported on initial exposure or re-exposure. If a severe hypersensitivity reaction occurs, therapy with Synagis should be permanently discontinued. If milder hypersensitivity reactions occur, caution should be used on re-administration of Synagis. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) have been reported.
In clinical trials, the most common adverse events occurring at least 1% more frequently in Synagis-treated patients than controls were upper respiratory infection, otitis media, fever, and rhinitis. Cyanosis and arrhythmia were seen in children with CHD. There have also been post-marketing reports of injection site reactions.
Click here for full Prescribing Information.